A double blind randomized placebo controlled pilot study of the serum amyloid P com[p]onent binding inhibitor CPHPC [RO 638695] in patients with osteoarthritis to assess tolerability, safety, and efficacy over a period of 24 weeks. Particular items discussed...

Trial Profile

A double blind randomized placebo controlled pilot study of the serum amyloid P com[p]onent binding inhibitor CPHPC [RO 638695] in patients with osteoarthritis to assess tolerability, safety, and efficacy over a period of 24 weeks. Particular items discussed...

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2005

At a glance

  • Drugs RO 638695 (Primary)
  • Indications Osteoarthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Jul 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top